Filing Details
- Accession Number:
- 0000950170-24-082476
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-09 17:01:29
- Reporting Period:
- 2024-07-05
- Accepted Time:
- 2024-07-09 17:01:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1400971 | L Bradley Campbell | 47 Hulfish Street Princeton NJ 08542 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-07-05 | 6,100 | $8.61 | 892,754 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-07-05 | 6,100 | $10.00 | 886,654 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (right to buy) | Disposition | 2024-07-05 | 6,100 | $0.00 | 6,100 | $8.61 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
37,500 | 2025-01-02 | No | 4 | M | Direct |
Footnotes
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.02 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of the options were fully vested and exercisable as of the transaction date.